Though actual date is hard to pin down with the firm having garnered siginificant SBIR support in the first few years of operation, the firm is discontinued operations. Medros utilized Drosophila to take a novel, whole animal approach to drug discovery for cancer metastasis and for diabetes-related diseases. Founded on the scientifically validated premise that traditional methods of gene discovery neglect the complex tissue and cell interactions that occur in the context of a whole animal, the Company offered drug discovery screening, target identification and validation to the pharmaceutical industry.
